Efficacy of treatment with a basal-prandial insulin regimen in patients with type 2 diabetes mellitus previously treated with premixed insulin

被引:1
|
作者
Javier Garcia-Soidan, Francisco [1 ]
机构
[1] Ctr Salud Porrino, Pontevedra, Spain
来源
AVANCES EN DIABETOLOGIA | 2013年 / 29卷 / 01期
关键词
Type 2 diabetes mellitus; Premixed insulin; Basal-prandial therapy; Glycaemic control; Primary health care;
D O I
10.1016/j.avdiab.2013.01.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Premixed insulins are a common treatment for type 2 diabetes mellitus (DM). However, their limitations and the lack of achieving glycaemic control in some patients reinforce the need to find therapeutic alternatives. Objectives: To assess whether basal-prandial therapy (basal insulin, and additional pre-prandial rapid insulin boluses, when required) improves glycaemic control in patients with type 2 DM and glycosylated haemoglobin (HbA1c) >53 mmol/mol (7%) treated with premixed insulin in the primary care setting. Material and methods: A retrospective observational study in which 116 patients with type 2 DM switched from premixed insulin to basal-prandial therapy. Data on demographics, anthropo-metrics, laboratory results, and antidiabetic treatment were collected from the medical charts of the patients, prior to switching the treatment (baseline) and 4 months thereafter. Results: HbA1c significantly decreased from baseline to month 4 (65.1 +/- 5.7 mmol/mol [8.1 +/- 0.5%] versus 51.9 +/- 7.2 mmol/mol [6.9 +/- 0.7%]; p < .005), and 70 patients (60.9%) had an HbA1c <= 53 mmol/mol (7%). Additionally, fasting blood glucose (FBG) significantly decreased (9.7 +/- 1.7 mmol/l [175.4 +/- 31.2 mg/dl] versus 6.9 +/- 1.4 mmol/l [124.4 +/- 25.8 mg/dl]; p < .005), and the number of patients with FBG < 5.6 mmol/l (100 mg/dl) (2 patients [1.7%] versus 21 patients [18.3%]; p < .005), and with post-prandial blood glucose <= 10 mmol/l (180 mg/dl) (14 patients, [12.1%] versus 87 patients [76.3%]; p < .05) significantly increased. There were also significant decreases in body weight (76.3 +/- 12.9 kg versus 74.8 +/- 12.5 kg; p < .001) and waist circumference (96.1 +/- 16.0 cm versus 94.4 +/- 14.5 cm; p < .005). Only 4 patients (3.5%) had hypoglycaemia. Conclusions: Basal-prandial therapy improved glycaemic control in patients with type 2 DM, with a low incidence of hypoglycaemia, and decreased body weight. (C) 2012 Sociedad Espanola de Diabetes. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 50 条
  • [21] Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
    Buse, John B.
    Rodbard, Helena W.
    Serrano, Carlos Trescoli
    Luo, Junxiang
    Ivanyi, Tibor
    Bue-Valleskey, Juliana
    Hartman, Mark L.
    Carey, Michelle A.
    Chang, Annette M.
    DIABETES CARE, 2016, 39 (01) : 92 - 100
  • [22] Evaluation of Sliding-Scale Insulin Versus Basal-Prandial Insulin Use in Hospitalized Medicine Patients
    Rogers, Maegan
    Usery, Justin
    Self, Timothy
    Greenberg, Courtney
    Swanson, Heather
    DIABETES, 2011, 60 : A606 - A606
  • [23] Comparison of 2 Insulin Treatment Strategies with Premixed Formulations in Patients with Type 2 Diabetes Mellitus
    Farcasiu, Eugenia
    Birkus, Zita
    Csog, Jozsef
    Kiljanski, Jacek
    Kowalska, Irina
    Ivanyi, Tibor
    Coetzer, Thomas Frederic
    Burgurlu, Sami
    Wille, Simone
    Schinzel, Birgit
    Mozejko-Pastewka, Barbara
    DIABETES, 2010, 59 : A207 - A207
  • [24] Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus
    Gomez-Huelgas, R.
    Saban-Ruiz, J.
    Garcia-Roman, F. J.
    Quintela-Fernandez, N.
    Segui-Ripoll, J. M.
    Bonilla-Hernandez, M. V.
    Romero-Melia, G.
    REVISTA CLINICA ESPANOLA, 2017, 217 (04): : 201 - 206
  • [25] CLINICAL EFFICACY AND SAFETY OF INSULIN ASPART COMPARED WITH REGULAR HUMAN INSULIN IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS RECEIVING PRANDIAL INSULIN REGIMEN - A SYSTEMATIC REVIEW AND META-ANALYSIS
    Wojciechowski, P.
    Niemczyk-Szechowska, P.
    Olewinska, E.
    Jaros, P.
    Jurkiewicz, B.
    Skarzynska-Duk, J.
    Mlalecki, M. T.
    Rys, P.
    VALUE IN HEALTH, 2014, 17 (03) : A238 - A238
  • [26] Basal insulin glargine vs prandial insulin lispro in type 2 diabetes -: Reply
    Linn, Thomas
    Landgraf, W.
    Bretzel, Reinhard G.
    LANCET, 2008, 372 (9636): : 372 - 372
  • [27] Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin
    Blak, B. T.
    Smith, H. T.
    Hards, M.
    Curtis, B. H.
    Ivanyi, T.
    DIABETIC MEDICINE, 2012, 29 (07) : E13 - E20
  • [28] Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents - Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    Rosenstock, Julio
    Scism-Bacon, Jamie
    Ahmann, Andrew J.
    Jiang, Honghua
    Colon, Gildred
    Martin, Sherry
    DIABETES CARE, 2008, 31 (01) : 20 - 25
  • [29] Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
    Ito, Hiroyuki
    Abe, Mariko
    Antoku, Shinichi
    Omoto, Takashi
    Shinozaki, Masahiro
    Nishio, Shinya
    Mifune, Mizuo
    Togane, Michiko
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 391 - 396
  • [30] Telecare for patients with type 2 diabetes mellitus on an intensified insulin regimen
    Siegmund, Thorsten
    Blankenfeld, Hannes
    Von Amelunxen, Sylvia
    Mueller-Oeffner, Alexandra
    Schumm-Draeger, Patra-Maria
    DIABETES, 2008, 57 : A347 - A347